- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Susan Urba, MD, Discusses Treatments for CINV
Susan Urba, MD, Medical Director, Symptom Management & Supportive Care Program, University of Michigan, says that preventative medications given prior to treatment are necessary in order to improve the quality of life for patients with chemotherapy-induced nausea and vomiting (CINV).
Susan Urba, MD, Medical Director, Symptom Management & Supportive Care Program, University of Michigan, says that preventative medications given prior to treatment are necessary in order to improve the quality of life for patients with chemotherapy-induced nausea and vomiting (CINV).
Dr Urba says that vomiting is well controlled, but nausea is still a problem despite the preventative medication. "For now, prevention is the key," Dr Urba said. "Giving the adequate drugs for the category that the patient is in, and hopefully the patient's quality of life will improve."
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
